TY - JOUR
T1 - “I'm obviously not dying so it's not something I need to sort out today”
T2 - Considering hepatitis C treatment in the era of direct acting antivirals
AU - Wright, C.
AU - Cogger, S.
AU - Hsieh, K.
AU - Goutzamanis, S.
AU - Hellard, M.
AU - Higgs, P.
N1 - Funding Information:
MH and PH: Research/grant support from Gilead Sciences to the Burnet Institute to support an investigator initiated research study on treatment of PWID. Declaration of funding interests: Gilead Sciences provided funding to PH for the project through its Australian Fellowship Research Grants Program. MH was supported with a NHMRC Senior Research Fellowship . The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.
Publisher Copyright:
© 2018 Australasian College for Infection Prevention and Control
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2019/5
Y1 - 2019/5
N2 - Background: People who inject drugs are the group at greatest risk of hepatitis C virus (HCV) infection. The advent of new direct-acting antiviral (DAA) treatment provides opportunities for increased uptake of therapy. Methods: We conducted in-depth interviews with thirty HCV positive participants from the SuperMIX cohort study. Interviews were transcribed, coded, and analysed for emerging themes and similarities between participants. General descriptions and critical interpretation of themes were generated and selective quotes extracted verbatim to best illustrate the critical themes. Results: Participants described their experiences of living with HCV, their knowledge of HCV treatment accessibility, and information on the types of support ain themes: Understanding the need for treatment; Knowledge and framing of treatment access; and Support during treatment. Conclusion: The new, highly effective DAAs for the treatment of HCV are heralded as the potential beginning of HCV elimination, especially in settings where scale up is high. Our data from active PWID show that the availability of DAA medications in and of themselves is likely not to be enough to ensure that PWID will come forward for HCV treatment in sufficient numbers to drive elimination.
AB - Background: People who inject drugs are the group at greatest risk of hepatitis C virus (HCV) infection. The advent of new direct-acting antiviral (DAA) treatment provides opportunities for increased uptake of therapy. Methods: We conducted in-depth interviews with thirty HCV positive participants from the SuperMIX cohort study. Interviews were transcribed, coded, and analysed for emerging themes and similarities between participants. General descriptions and critical interpretation of themes were generated and selective quotes extracted verbatim to best illustrate the critical themes. Results: Participants described their experiences of living with HCV, their knowledge of HCV treatment accessibility, and information on the types of support ain themes: Understanding the need for treatment; Knowledge and framing of treatment access; and Support during treatment. Conclusion: The new, highly effective DAAs for the treatment of HCV are heralded as the potential beginning of HCV elimination, especially in settings where scale up is high. Our data from active PWID show that the availability of DAA medications in and of themselves is likely not to be enough to ensure that PWID will come forward for HCV treatment in sufficient numbers to drive elimination.
KW - HCV treatment
KW - Hepatitis C
KW - Models of care
KW - People who inject drugs
UR - http://www.scopus.com/inward/record.url?scp=85057411125&partnerID=8YFLogxK
U2 - 10.1016/j.idh.2018.10.006
DO - 10.1016/j.idh.2018.10.006
M3 - Article
C2 - 30541692
AN - SCOPUS:85057411125
VL - 24
SP - 58
EP - 66
JO - Infection, Disease and Health
JF - Infection, Disease and Health
SN - 2468-0451
IS - 2
ER -